David Scott Miller


AuthID: R-00K-250

Confirmed Publications: 293



171
TITLE: Survival impact of clinical trials in patients with recurrent cervical cancer  Full Text
AUTHORS: Nagel, C; Denson, W; Rogers, P; Manders, D; Richardson, D; Kehoe, S; David Scott Miller ; Lea, J;
PUBLISHED: 2011, SOURCE: Gynecologic Oncology, VOLUME: 123, ISSUE: 2
INDEXED IN: CrossRef
IN MY: ORCID
172
TITLE: The role of lymphadenectomy in endometrial cancer
AUTHORS: Siobhan M Kehoe; David Scott Miller ;
PUBLISHED: 2011, SOURCE: Clinical Obstetrics and Gynecology, VOLUME: 54, ISSUE: 2
INDEXED IN: Scopus CrossRef: 25
IN MY: ORCID
173
TITLE: Third-line salvage chemotherapy for recurrent cervical cancer.
AUTHORS: Manders, DB; Purinton, SC; Lea, J; David Scott Miller ; Kehoe, SM; Richardson, DL;
PUBLISHED: 2011, SOURCE: Journal of Clinical Oncology, VOLUME: 29, ISSUE: 15_suppl
INDEXED IN: CrossRef
IN MY: ORCID
174
TITLE: A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: A gynecologic oncology group trial. A Gynecologic Oncology Group Trial
AUTHORS: Russell J Schilder; John A Blessing; Mark S Shahin; David Scott Miller ; Krishnansu Sujata Tewari; Carolyn Y Muller; David P Warshal; Scott McMeekin; Jacob Rotmensch;
PUBLISHED: 2010, SOURCE: International Journal of Gynecological Cancer, VOLUME: 20, ISSUE: 7
INDEXED IN: Scopus CrossRef: 13
IN MY: ORCID
175
TITLE: An update on endometrial cancer
AUTHORS: Todd Boren; David Scott Miller ;
PUBLISHED: 2010, SOURCE: Texas medicine, VOLUME: 106, ISSUE: 9
INDEXED IN: Scopus
IN MY: ORCID
176
TITLE: PRO: All patients with serous and clear cell carcinomas of the endometrium should receive chemotherapy as part of their treatment  Full Text
AUTHORS: Todd P Boren; David Scott Miller ;
PUBLISHED: 2010, SOURCE: Clinical Ovarian Cancer, VOLUME: 3, ISSUE: 2
INDEXED IN: Scopus CrossRef
IN MY: ORCID
177
TITLE: Promoter hypermethylation of CIDEA, HAAO and RXFP3 associated with microsatellite instability in endometrial carcinomas  Full Text
AUTHORS: Yi Wen Huang; Jingqin Luo; Yu I Weng; David G Mutch; Paul J Goodfellow; David Scott Miller ; Tim H M Huang;
PUBLISHED: 2010, SOURCE: Gynecologic Oncology, VOLUME: 117, ISSUE: 2
INDEXED IN: Scopus CrossRef: 36
IN MY: ORCID
178
TITLE: Should all patients with serous and clear cell endometrial carcinoma receive adjuvant chemotherapy?
AUTHORS: Todd P Boren; David Scott Miller ;
PUBLISHED: 2010, SOURCE: Women's Health, VOLUME: 6, ISSUE: 6
INDEXED IN: Scopus CrossRef: 2
IN MY: ORCID
179
TITLE: The correlation of cone biopsy with findings at radical hysterectomy and the need for adjuvant radiation therapy.
AUTHORS: Boren, TP; Richardson, DL; Kehoe, SM; David Scott Miller ;
PUBLISHED: 2010, SOURCE: Journal of Clinical Oncology, VOLUME: 28, ISSUE: 15_suppl
INDEXED IN: CrossRef
IN MY: ORCID
180
TITLE: A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology  Full Text
AUTHORS: David Scott Miller ; John A Blessing; Richard D Drake; Robert Higgins; Scott S McMeekin; Louis V Puneky; Carolyn N Krasner;
PUBLISHED: 2009, SOURCE: Gynecologic Oncology, VOLUME: 115, ISSUE: 3
INDEXED IN: Scopus CrossRef: 31
IN MY: ORCID
Page 18 of 30. Total results: 293.

A place for researchers and their institutions

Useful Links

Get Help

© 2024 CRACS & Inesc TEC - All Rights Reserved Privacy Policy | Terms of Service